Efficacy and Safety of Lemborexant for Insomnia Patients With Nocturia—A Prospective Study
LUTS: Lower Urinary Tract Symptoms · 2024
DOI: 10.1111/luts.12534 ↗Kurz gefasst
Fachartikel in der Zeitschrift LUTS: Lower Urinary Tract Symptoms, 2024. Verfasst von Yoshikazu Togo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kawanishi City Medical Center, Hyogo, Japan. Hauptthemen laut MEDLINE: Sleep Initiation and Maintenance Disorders, Nocturia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Themen: Schlaf
Abstract (Originalsprache)
Objectives
Nocturia is considered a clinical problem when nocturnal urinary frequency is two or more times. For affected patients, development of depression, falling, and increased mortality rate are matters of concern. The present study investigated the efficacy and safety of lemborexant for insomnia patients with nocturia.
Methods
Insomnia patients (Athens Insomnia Scale [AIS] ≥ 6) who typically awoke twice or more during the night to urinate and were examined at our institutions from June 2021 to December 2022 were enrolled. Each was administrated 5 mg of lemborexant, one tablet, daily for 4 weeks. Total AIS score, nocturia frequency, individual frequency‐volume chart findings, and N‐QOL score were examined before and after administration.
Results
Of the 37 patients recruited, 5 were excluded, thus 32 were enrolled and subjected to analyses. Following lemborexant therapy, the mean AIS total score was significantly decreased from 11.4 to 7.8 ( p < 0.01) as was mean number of nocturia episodes from 3.4 to 2.3 ( p < 0.001). Furthermore, the mean single voided urine volume at night was significantly increased from 182.5 to 225.3 mL ( p < 0.001)and mean period of undisturbed sleep was significantly extended from 105.3 to 174.8 min ( p < 0.001), while mean total N‐QOL score was significantly improved from 49.6% to 64.8% ( p < 0.001). As for adverse events, mild somnolence was observed in three cases.
Conclusions
Lemborexant may be effective and safe for use in insomniac patients with nocturia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Kawanishi City Medical Center, Hyogo, Japan.
- Department of Palliative Medicine, Kyoritsu Kinen Hospital, Hyogo, Japan.
- Taguchi Urology Clinic, Hyogo, Japan.
ORCID-Profile: Yoshikazu Togo
Zitieren
APA
Togo, Y., Kaizuka, Y., Nagasawa, S., Kajio, K., Kondoh, N., & Taguchi, K. (2024). Efficacy and Safety of Lemborexant for Insomnia Patients With Nocturia—A Prospective Study. LUTS: Lower Urinary Tract Symptoms. https://doi.org/10.1111/luts.12534
Vancouver
Togo Y, Kaizuka Y, Nagasawa S, Kajio K, Kondoh N, Taguchi K. Efficacy and Safety of Lemborexant for Insomnia Patients With Nocturia—A Prospective Study. LUTS: Lower Urinary Tract Symptoms. 2024. doi:10.1111/luts.12534
BibTeX
@article{Togo2024,
author = {Togo, Yoshikazu and Kaizuka, Yohei and Nagasawa, Seiji and Kajio, Keisuke and Kondoh, Nobuyuki and Taguchi, Keizo},
title = {Efficacy and Safety of Lemborexant for Insomnia Patients With Nocturia—A Prospective Study},
journal = {LUTS: Lower Urinary Tract Symptoms},
year = {2024},
doi = {10.1111/luts.12534}
}
EUVIMED